Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat

European Journal of Pharmacology

Volumn 477, Issue 2, 2003, Pages 101-112

  McCullumsmith, Robert E ^a   Stincic, Todd L ^a   Agrawal, Smriti M ^a   Meador Woodruff, James H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Clozapine; Haloperidol; Neuroleptic; Olanzapine; Oral dyskinesia; Striatum

Indexed keywords

CLOZAPINE; DECANOIC ACID; DELTA OPIATE RECEPTOR; DOPAMINE RECEPTOR; GLUTAMATE DECARBOXYLASE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; PREPROENKEPHALIN; PRODYNORPHIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; GLOBUS PALLIDUS; MALE; MASTICATION; NEUROCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CLOZAPINE; DYSKINESIA, DRUG-INDUCED; GENE EXPRESSION; HALOPERIDOL; IN SITU HYBRIDIZATION; INJECTIONS, INTRAMUSCULAR; MALE; MASTICATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER;

EID: 1642308000     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.08.018     Document Type: Article

References (62)

1. Andreassen O.A., Jorgensen H.A. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. Psychopharmacology (Berl.). 116:1994;517-522.
2. Andreassen O.A., Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 61:2000;525-541.
3. Andreassen O.A., Aamo T.O., Joorgensen H.A. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br. J. Pharmacol. 119:1996;751-757.
4. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
5. Caroff S.N., Mann S.C., Campbell E.C., Sullivan K.A. Movement disorders associated with atypical antipsychotic drugs. J. Clin. Psychiatry. 63:2002;12-19.
6. Clow A., Jenner P., Marsden C.D. Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Eur. J. Pharmacol. 57:1979;365-375.
7. Cobb W.S., Abercrombie E.D. Differential regulation of somatodendritic and nerve terminal dopamine release by serotonergic innervation of substantia nigra. J. Neurochem. 84:2003;576-584.
8. De Keyser K. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin. Neuropharmacol. 14:1991;562-565.
9. Delfs J.M., Anegawa N.J., Chesselet M.F. Glutamate decarboxylase messenger RNA in rat pallidum: comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments. Neuroscience. 66:1995;67-80.
10. Delfs J.M., Ellison G.D., Mercugliano M., Chesselet M.F. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp. Neurol. 133:1995;175-188.
11. De Souza I.E., McBean G.J., Meredith G.E. Chronic haloperidol treatment impairs glutamate transport in the rat striatum. Eur. J. Pharmacol. 382:1999;139-142.
12. Diana M., Collu M., Mura A., Gessa G.L. Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine. Eur. J. Pharmacol. 211:1992;415-419.
13. Downs A.M., Williams M.A. An improved approach to the analysis of autoradiographs containing isolated sources of simple shape: method, theoretical basis and reference data. J. Microsc. 136:1984;1-22.
14. Drew K.L., O'Connor W.T., Kehr J., Ungerstedt U. Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur. J. Pharmacol. 187:1990;385-397.
15. Egan M.F., Hurd Y., Ferguson J., Bachus S.E., Hamid E.H., Hyde T.M. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl.). 127:1996;337-345.
16. Gao X.M., Sakai K., Tamminga C.A. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Neuropsychopharmacology. 19:1998;428-433.
17. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15:1992;133-139.
18. Glazer W.M. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J. Clin. Psychiatry. 61:2000;21-26.
19. Glazer W.M. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J. Clin. Psychiatry. 61:2000;15-20.
20. Grimm J.W., Kruzich P.J., See R.E. Emergence of oral and locomotor activity in chronic haloperidol-treated rats following cortical N-methyl-D-aspartate stimulation. Pharmacol. Biochem. Behav. 60:1998;167-173.
21. Gunne L.M., Growdon J.H. A model for oral dyskinesia in rats. J. Clin. Psychopharmacol. 2:1982;308-311.
22. Gunne L.M., Growdon J., Glaeser B. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology. 77:1982;134-139.
23. Gunne L.M., Andersson U., Bondesson U., Johansson P. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol. Biochem. Behav. 25:1986;897-901.
24. Hashimoto T., Ross D.E., Gao X.M., Medoff D.R., Tamminga C.A. Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. Psychopharmacology (Berl.). 137:1998;107-112.
25. Healy D.J., Meador-Woodruff J.H. Glutamatergic modulation of subcortical motor and limbic circuits. Ann. N.Y. Acad. Sci. 877:1999;684-687.
26. Heimer L., Alheid G.F., Zahm D.S. Limbic Motor Circuits and Neuropsychiatry. 1993;1-32 CRC Press, Ann Arbor.
27. Ibrahim H.M., Healy D.J., Hogg A.J., Meador-Woodruff J.H. Jr. Nucleus-specific expression of ionotropic glutamate receptor subunit mRNAs and binding sites in primate thalamus. Brain Res. Mol. Brain Res. 79:2000;1-17.
28. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76:2001;1521-1531.
29. Ikeda H., Adachi K., Hasegawa M., Sato M., Hirose N., Koshikawa N., Cools A.R. Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia. J. Neural Transm. 106:1999;1205-1216.
30. Iversen S.D., Howells R.B., Hughes R.P. Behavioral consequences of long-term treatment with neuroleptic drugs. Adv. Biochem. Psychopharmacol. 24:1980;305-313.
31. Jeste D.V., Lohr J.B., Eastham J.H., Rockwell E., Caligiuri M.P. Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J. Psychiatr. Res. 32:1998;201-214.
32. Johansson P., Levin E., Gunne L., Ellison G. Opposite effects of a D1 and a D2 agonist on oral movements in rats. Eur. J. Pharmacol. 134:1987;83-88.
33. Julius D., Huang K.N., Livelli T.J., Axel R., Jessell T.M. The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proc. Natl. Acad. Sci. U. S. A. 87:1990;928-932.
34. Kakigi T., Gao X.M., Tamminga C.A. Drug-induced oral dyskinesias in rats after traditional and new neuroleptics. J. Neural Transm. Gen. Sect. 101:1995;41-49.
35. Kia H.K., Miquel M.C., Brisorgueil M.J., Daval G., Riad M., El Mestikawy S., Hamon M., Verge D. Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J. Comp. Neurol. 365:1996;289-305.
36. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl.). 124:1996;2-34.
37. Mansour A., Thompson R.C., Akil H., Watson S.J. Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA. J. Chem. Neuroanat. 6:1993;351-362.
38. Marchese G., Casu M.A., Bartholini F., Ruiu S., Saba P., Gessa G.L., Pani L. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur. J. Neurosci. 15:2002;1187-1196.
39. Meador-Woodruff J.H., Mansour A., Civelli O., Watson S.J. Distribution of D2 dopamine receptor mRNA in the primate brain. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 15:1991;885-893.
40. Meador-Woodruff J.H., Mansour A., Grandy D.K., Damask S.P., Civelli O., Watson S.J. Jr. Distribution of D5 dopamine receptor mRNA in rat brain. Neurosci. Lett. 145:1992;209-212.
41. Meador-Woodruff J.H., Damask S.P., Watson S.J. Jr. Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8297-8301.
42. Meador-Woodruff J.H., Haroutunian V., Powchik P., Davidson M., Davis K.L., Watson S.J. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch. Gen. Psychiatry. 54:1997;1089-1095.
43. Mercugliano M., Saller C.F., Salama A.I., U'Prichard D.C., Chesselet M.F. Clozapine and haloperidol have differential effects on glutamic acid decarboxylase mRNA in the pallidal nuclei of the rat. Neuropsychopharmacology. 6:1992;179-187.
44. Moore N.A., Tye N.C., Axton M.S., Risius F.C. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J. Pharmacol. Exp. Ther. 262:1992;545-551.
45. Oh-e Y., Miyazaki H., Matsunaga Y., Hashimoto M. Pharmacokinetics of haloperidol decanoate in rats. J. Pharmacobio-dyn. 14:1991;615-622.
46. Ohno Y., Ishida-Tokuda K., Ishibashi T., Nakamura M. Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity. Pharmacol. Biochem. Behav. 57:1997;889-895.
47. Rajakumar N., Laurier L., Niznik H.B., Stoessl A.J. Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine-induced behaviors in the rat. Synapse. 26:1997;199-208.
48. Riad M., Garcia S., Watkins K.C., Jodoin N., Doucet E., Langlois X., el Mestikawy S., Hamon M., Descarries L. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J. Comp. Neurol. 417:2000;181-194.
49. Roberts R.C. Effect of chronic olanzapine treatment on striatal synaptic organization. Synapse. 39:2001;8-15.
50. Rosengarten H., Friedhoff A.J. A phosphoinositide-linked dopamine D1 receptor mediates repetitive jaw movements in rats. Biol. Psychiatry. 44:1998;1178-1184.
51. Rosengarten H., Quartermain D. The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen-month-old rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;1047-1054.
52. Rupniak N.M., Hall M.D., Mann S., Fleminger S., Kilpatrick G., Jenner P., Marsden C.D. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem. Pharmacol. 34:1985;2755-2763.
53. Sadock, B.J., Sadock, V.A., 2000. Comprehensive Textbook of Psychiatry. Lippincott, Williams and Wilkins, Philadelphia, pp. 978-979.
54. Sakai K., Gao X.M., Hashimoto T., Tamminga C.A. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse. 39:2001;152-160.
55. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.). 124:1996;57-73.
56. See R.E., Berglind W.J. Decreased pallidal GABA following reverse microdialysis with clozapine, but not haloperidol. NeuroReport. 12:2001;3655-3658.
57. See R.E., Chapman M.A. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur. J. Pharmacol. 263:1994;269-276.
58. Tamminga C.A., Thaker G.K., Moran M., Kakigi T., Gao X.M. Clozapine in tardive dyskinesia: observations from human and animal model studies. J. Clin. Psychiatry. 55(Suppl B):1994;102-106.
59. Tarsy D., Baldessarini R.J., Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 16:2002;23-45.
60. Turrone P., Remington G., Nobrega J.N. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci. Biobehav. Rev. 26:2002;361-380.
61. Williams M.A. Autoradiography: its methodology at the present time. J. Microsc. 128:1982;79-94.
62. Yu J., Kallstrom L., Wiesel F.A., Johnson A.E. Neurochemical changes in the entopeduncular nucleus and increased oral behavior in rats treated subchronically with clozapine or haloperidol. Synapse. 34:1999;192-207.